<?xml version="1.0" encoding="UTF-8"?>
<p id="para0027">In addition, another promising guanine analog is favipiravir (T-705), which has been approved in Japan for the therapy of influenza virus infections and has also been demonstrated to suppress the replication of Ebola, yellow fever, enterovirus and norovirus 
 <xref rid="bib0078" ref-type="bibr">[78]</xref>. Recently, Wang and coworkers suggested that favipiravir may also be a potential candidate for COVID-19 therapy, which showed effective antiviral activity in Vero E6 cells with an EC50 value of around 61 μM. To improve the condition of COVID-19 patients, favipiravir was utilized with other antiviral drugs like baloxavir marboxil 
 <xref rid="bib0088" ref-type="bibr">[88]</xref>.
</p>
